Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Expected to Post Earnings of -$0.14 Per Share

Share on StockTwits

Equities research analysts expect Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to report ($0.14) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Achillion Pharmaceuticals’ earnings. Achillion Pharmaceuticals reported earnings per share of ($0.12) during the same quarter last year, which would indicate a negative year over year growth rate of 16.7%. The company is expected to issue its next earnings report on Wednesday, August 14th.

On average, analysts expect that Achillion Pharmaceuticals will report full year earnings of ($0.59) per share for the current year. For the next financial year, analysts expect that the business will post earnings of ($0.67) per share. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Achillion Pharmaceuticals.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.14).

ACHN has been the topic of several analyst reports. BidaskClub cut Ames National from a “hold” rating to a “sell” rating in a research report on Wednesday. ValuEngine upgraded Vale from a “sell” rating to a “hold” rating in a research report on Tuesday. Barclays set a $24.00 price target on Orion Engineered Carbons and gave the company a “hold” rating in a research report on Friday, May 3rd. Finally, Zacks Investment Research raised Investar from a “hold” rating to a “buy” rating and set a $27.00 price objective for the company in a report on Tuesday, June 4th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and one has issued a buy rating to the stock. Achillion Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $2.75.

Achillion Pharmaceuticals stock traded up $0.02 during midday trading on Thursday, reaching $2.42. The stock had a trading volume of 529,377 shares, compared to its average volume of 1,497,810. The business has a 50-day moving average of $2.74. Achillion Pharmaceuticals has a 12 month low of $1.29 and a 12 month high of $3.98. The firm has a market cap of $327.40 million, a price-to-earnings ratio of -4.75 and a beta of 1.88.

A number of institutional investors and hedge funds have recently modified their holdings of ACHN. Metropolitan Life Insurance Co NY purchased a new stake in shares of Achillion Pharmaceuticals in the first quarter worth about $131,000. MetLife Investment Advisors LLC purchased a new stake in shares of Achillion Pharmaceuticals in the first quarter worth about $200,000. Mak Capital One LLC boosted its stake in shares of Achillion Pharmaceuticals by 33.5% in the first quarter. Mak Capital One LLC now owns 6,929,653 shares of the biopharmaceutical company’s stock worth $20,512,000 after buying an additional 1,738,053 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its stake in shares of Achillion Pharmaceuticals by 22.1% in the first quarter. DekaBank Deutsche Girozentrale now owns 66,300 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 12,000 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its stake in shares of Achillion Pharmaceuticals by 973.1% in the first quarter. Acadian Asset Management LLC now owns 278,573 shares of the biopharmaceutical company’s stock worth $825,000 after buying an additional 252,613 shares during the last quarter. 79.30% of the stock is owned by institutional investors and hedge funds.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.

Recommended Story: How do candlesticks reflect price movement?

Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.